What Is Claimed Is:

1. A method of treating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula V:



(V)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

2. The method of claim 1, wherein said compound is of Formula I:



(I)

or pharmaceutically acceptable salts or prodrugs thereof, wherein:

A is N or C-R_8, B is N or C-R_9, D is N or C-R_{10}, E is N or C-R_6 and F is N or C-R_7, provided that not more than two of A, B, D, E and F are N in the same time;

Ar is optionally substituted and is an aryl or heteroaryl;

R_6-R_{10} are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl,

heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen or optionally substituted alkyl, cycloalkyl, aryl, or heteroaryl.

3. The method of claim 2, wherein A is N, B is C-R_9 and F is C-R_7.

4. The method of claim 1, wherein Ar′ is optionally substituted and is furyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl.

5. The method of claim 4, wherein Ar′ is optionally substituted furyl.

6. The method of claim 5, wherein Ar is optionally substituted phenyl.

7. The method of claim 6, wherein Ar′ is optionally substituted 3-furyl.

8. The method of claim 7, wherein Ar′ is unsubstituted 3-furyl.

9. The method of claim 8, wherein said compound is *N*-(4-ethoxy-2-nitrophenyl)-3-furancarboxamide.

10. The method of claim 4, wherein Ar′ is optionally substituted pyrrolyl.

11. The method of claim 10, wherein Ar is optionally substituted phenyl.

12. The method of claim 11, wherein Ar′ is optionally substituted 3-pyrrolyl.

13. The method of claim 12, wherein Ar′ is unsubstituted 3-pyrrolyl.

14. The method of claim 13, wherein said compound is *N*-(4-ethoxy-2-nitrophenyl)-3-pyrrolecarboxamide.

15. The method of claim 4, wherein Ar′ is optionally substituted phenyl.

16. The method of claim 15, wherein Ar is optionally substituted phenyl.

17. The method of claim 16, wherein said compound is selected from the group consisting of:

4-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-benzoylamide; and

4-Chloromethyl-*N*-(4-ethoxy-2-nitrophenyl)-benzoylamide.

18. The method of claim 15, wherein Ar is optionally substituted pyridyl.

19. The method of claim 18, wherein said compound is selected from the group consisting of:

4-Chloro-2-nitro-*N*-(6-chloro-3-pyridyl)-benzoylamide;

4-Chloro-2-nitro-*N*-(6-methyl-3-pyridyl)-benzoylamide; and

4-Bromomethyl-3-nitro-*N*-(6-chloro-3-pyridyl)-benzoylamide.

20. The method of claim 4, wherein Ar′ is optionally substituted pyrazinyl.

21. The method of claim 20, wherein Ar is optionally substituted phenyl.

22. The method of claim 21, wherein Ar′ is 3-pyrazinyl.

23. The method of claim 22, wherein said compound is selected from the group consisting of:

6-Methyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyrazinecarboxamide; and

N-(4-Ethoxy-2-nitrophenyl)-3-pyrazinecarboxamide.

24. The method of claim 4, wherein Ar′ is optionally substituted pyrimidinyl.

25. The method of claim 24, wherein Ar is optionally substituted phenyl.

26. The method of claim 25, wherein Ar′ is optionally substituted 5-pyrimidinyl.

27. The method of claim 26, wherein said compound is *N*-(4-ethoxy-2-nitrophenyl)-5-pyrimidinecarboxamide.

28. The method of claim 4, wherein Ar′ is optionally substituted pyridyl.

29. The method of claim 28, wherein Ar is optionally substituted phenyl.

30. The method of claim 29, wherein Ar′ is optionally substituted 2-pyridyl.

31. The method of claim 30, wherein said compound is selected from the group consisting of:

N-(4-Ethoxy-2-nitrophenyl)-2-pyridinecarboxamide; and

N-(4-Ethoxy-2-nitrophenyl)-1-*N*-oxide-2-pyridinecarboxamide.

32. The method of claim 29, wherein Ar′ is optionally substituted 3-pyridyl.

33. The method of claim 32, wherein said compound is of Formula III:



(III)

or a pharmaceutically acceptable salt or prodrug thereof, wherein

R_1-R_7 and R_9-R_{10} are independently hydrogen, halo, haloalkyl, haloalkoxy, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl,

arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, aminoalkyl, cyano, cyanoalkyl, acyl, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, alkoxycarbonyl, aryloxy, arylalkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

34. The method of claim 33, wherein R_1 and R_2, or R_2 and R_3, or R_3 and R_4, or R_4 and R_5 are taken together to form an optionally substituted carbocycle or an optionally substituted heterocycle.

35. The method of claim 34, wherein said R_1 and R_2, or R_2 and R_3, or R_3 and R_4, or R_4 and R_5 are taken together to form $-OCH_2O-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-OCH_2CH_2O-$, $-CH_2N(R)CH_2-$, $-CH_2CH_2N(R)CH_2-$, $-CH_2N(R)CH_2CH_2-$, $-CH=CH-CH=CH-$, $-N(R)-CH=CH-$, $-CH=CH-N(R)-$, $-O-CH=CH-$, $-CH=CH-O-$, $-S-CH=CH-$, $-CH=CH-S-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$ or $-N=CH-CH=N-$, wherein the carbocycle or heterocycle is optionally substituted, and R is hydrogen, alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

36. The method of claim 33, wherein R_6, R_7 and R_{10} are independently hydrogen or fluoro.

37. The method of claim 33, wherein R_1 is nitro.

38. The method of claim 33, wherein R_2, R_4, and R_5 are independently hydrogen or fluoro.

39. The method of claim 33, wherein said compound is selected from the group consisting of:

N-(4-Methyl-2-nitrophenyl)-3-pyridinecarboxamide;

N-(4-Ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

N-(4-Methoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4,5-difluoro-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(3-bromo-4-methoxy-6-nitrophenyl)-3-pyridinecarboxamide;

5,6-Dichloro-*N*-(4-methoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2-methyl-4-methoxyphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-*N*-methyl-3-pyridinecarboxamide;

6-Chloro-*N*-(2-cyano-4,5-dimethoxyphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-trifluoromethylphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-cyanophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2,4-dimethyl-6-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(3,4-dimethoxy-6-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2-cyano-4-methylphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-methyl-6-nitrophenyl)-3-pyridinecarboxamide; and

4-Trifluoromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide.

40. The method of claim 33, wherein said compound is of Formula IV:



(IV)

or a pharmaceutically acceptable salt or prodrug thereof.

41. The method of claim 40, wherein said compound is selected from the group consisting of:

6-Chloro-*N*-(4-methoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-methyl-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-methoxy-2-nitrophenyl)-1-*N*-oxide-3-pyridinecarboxamide;
6-Chloro-*N*-(4-chloro-2-nitrophenyl)-3-pyridinecarboxamide;
6-Fluoro-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-fluoro-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-trifluoromethyl-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(2-nitro-4-trifluoromethoxylphenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-benzyloxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Methyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-cyano-2-nitrophenyl)-3-pyridinecarboxamide;
6-(2,2,2-Trifluoroethoxy)-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Dimethylamino-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;
6-Chloro-*N*-(4-*t*-butyl-2-nitrophenyl)-3-pyridinecarboxamide;
6-Trifluoromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide; and
6-Chloromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide.

42. A method for treating or preventing cancer, comprising administering to an animal in need of such treatment an effective amount of a compound of Formula V:



(V)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

43. The method of claim 42, wherein said compound is of Formula I:



(I)

or pharmaceutically acceptable salts or prodrugs thereof, wherein:

A is N or C-R_8, B is N or C-R_9, D is N or C-R_{10}, E is N or C-R_6 and F is N or C-R_7, provided that not more than two of A, B, D, E and F are N in the same time;

Ar is optionally substituted and is an aryl or heteroaryl;

R_6-R_{10} are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen or optionally substituted alkyl, cycloalkyl, aryl, or heteroaryl.

44. The method of claim 42, wherein Ar′ is optionally substituted and is furyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl.

45. The method of claim 42, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's

sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.

46. A method for the treatment of drug resistant cancer, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula V:



(V)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

47. The method of claim 46, wherein said compound is of Formula I:



(I)

or pharmaceutically acceptable salts or prodrugs thereof, wherein:

A is N or C-R_8, B is N or C-R_9, D is N or C-R_{10}, E is N or C-R_6 and F is N or C-R_7, provided that not more than two of A, B, D, E and F are N in the same time;

Ar is optionally substituted and is an aryl or heteroaryl;

R_6-R_{10} are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen or optionally substituted alkyl, cycloalkyl, aryl, or heteroaryl.

48. The method of claim 46, wherein Ar′ is optionally substituted and is furyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl.

49. The method of claim 42 or 46, additionally comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

50. The method of claim 49, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan® and alanosine.

51. The method of claim 42 or 46, additionally comprising treating said animal with radiation-therapy.

52. The method of claim 42 or 46, wherein said compound is administered after the surgical treatment of said animal for cancer.

53. The method of claim 1, wherein said disorder is an autoimmune disease.

54. The method of claim 1, wherein said disorder is rheumatoid arthritis.

55. The method of claim 1, wherein said disorder is inflamatory bowel disease.

56. The method of claim 1, wherein said disorder is a skin disease.

57. The method of claim 56, wherein said disorder is psoriasis.

58. A compound of Formula III:



(III)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 and R_5 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halogen, NO_2, cyano, haloalkyl, haloalkoxy, amino and aminoalkyl, provided that at least one of R_1 and R_5 is selected from the group consisting of NO_2, cyano, alkyl and haloalkyl;

R_2 and R_4 are independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, haloalkyl, haloalkoxy, amino and aminoalkyl;

R_3 is alkyl, Cl, F, haloalkyl, alkoxy, arylalkoxy, cyano, haloalkyloxy, amino or aminoalkyl;

R_6 is hydrogen, hydroxy, alkyl, NO_2, cyano, haloalkyl, haloalkyloxy, amino or aminoalkyl;

R_7 is hydrogen, hydroxy, alkyl, NO_2, cyano, haloalkyl, haloalkyloxy, amino or aminoalkyl;

R_9 is hydroxy, alkyl, halogen, NO_2, haloalkyl, alkoxy, cyano, haloalkyloxy, amino or aminoalkyl;

R_{10} is hydrogen, hydroxy, alkyl, Cl, F, NO_2, cyano, haloalkyl, haloalkyloxy, amino or aminoalkyl; and

R_{11} is hydrogen, alkyl or haloalkyl.

59. The compound of claim 58, wherein said compound is selected from the group consisting of:

6-Chloro-*N*-(4,5-difluoro-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(3-bromo-4-methoxy-6-nitrophenyl)-3-pyridinecarboxamide;

5,6-Dichloro-*N*-(4-methoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2-methyl-4-methoxyphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-*N*-methyl-3-pyridinecarboxamide;

6-Chloro-*N*-(2-cyano-4,5-dimethoxyphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-trifluoromethylphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-cyanophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2,4-dimethyl-6-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(3,4-dimethoxy-6-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2-cyano-4-methylphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-methyl-6-nitrophenyl)-3-pyridinecarboxamide; and

4-Trifluoromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide.

60. The compound of claim 58, wherein said compound is of Formula IV:



(IV)

or a pharmaceutically acceptable salt or prodrug thereof.

61. The compound of claim 60, wherein said compound is selected from the group consisting of:

6-Chloro-*N*-(4-methoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-methyl-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-methoxy-2-nitrophenyl)-1-*N*-oxide-3-pyridinecarboxamide;

6-Chloro-*N*-(4-chloro-2-nitrophenyl)-3-pyridinecarboxamide;

6-Fluoro-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-fluoro-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-trifluoromethyl-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(2-nitro-4-trifluoromethoxylphenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-benzyloxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Methyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-cyano-2-nitrophenyl)-3-pyridinecarboxamide;

6-(2,2,2-Trifluoroethoxy)-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Dimethylamino-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide;

6-Chloro-*N*-(4-*t*-butyl-2-nitrophenyl)-3-pyridinecarboxamide;

6-Trifluoromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide; and

6-Chloromethyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyridinecarboxamide.

62. A compound of Formula (VI):



(VI)

or a pharmaceutically acceptable salt or prodrug thereof, wherein

R_1-R_5, R_7 and R_9-R_{10} are independently hydrogen, halo, haloalkyl, haloalkoxy, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl,

carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, aminoalkyl, cyano, cyanoalkyl, acyl, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, alkoxycarbonyl, aryloxy, arylalkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

63. The compound of claim 62, or a pharmaceutically acceptable salt thereof, with the prioviso that at least one of R_1 and R_5 is selected from the group consisting of NO_2, cyano, alkyl and haloalkyl.

64. The compound of claim 62 or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 and R_5 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, haloalkoxy, amino and aminoalkyl;

R_2 and R_4 are independently selected from the group consisting of hydrogen, hydroxy, halogen, haloalkyl, haloalkoxy, amino and aminoalkyl;

R_3 is alkyl, Cl, F, haloalkyl, alkoxy, arylalkoxy, cyano, haloalkoxy, amino or aminoalkyl;

R_7, R_9 and R_{10} are independently selected from the group consisting of hydrogen, hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, alkoxy, haloalkoxy, amino and aminoalkyl; and

R_{11} is hydrogen, alkyl or haloalkyl.

65. The compound of claim 64, wherein said compound is selected from the group consisting of:

6-Methyl-*N*-(4-ethoxy-2-nitrophenyl)-3-pyrazinecarboxamide; and

N-(4-Ethoxy-2-nitrophenyl)-3-pyrazinecarboxamide.

66. A compound of Formula (VII):



(VII)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1-R_3, R_5-R_{10} are independently hydrogen, halo, haloalkyl, haloalkoxy, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, aminoalkyl, cyano, cyanoalkyl, acyl, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, alkoxycarbonyl, aryloxy, arylalkoxy, carboxy, carbonylamido or alkylthiol; and

R_{11} is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted.

67. The compound of claim 66, or a pharmaceutically acceptable salt thereof, with the prioviso that at least one of R_6 and R_7 is selected from the group consisting of NO_2, cyano, alkyl and haloalkyl.

68. The compound of claim 67 or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1, R_2, R_3 and R_5 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, alkoxy, haloalkoxy, amino and aminoalkyl;

R_6 and R_7 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, haloalkoxy, amino and aminoalkyl;

R_8 and R_{10} are independently selected from the group consisting of hydrogen, hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, haloalkoxy, amino and aminoalkyl;

R_9 is hydroxy, alkyl, halogen, NO_2, cyano, haloalkyl, alkoxy, haloalkoxy, amino or aminoalkyl; and

R_{11} is hydroxy, alkyl or haloalky.

69. The compound of claim 68, wherein said compound is selected from the group consisting of:

4-Chloro-2-nitro-*N*-(6-chloro-3-pyridyl)-benzoylamide;

4-Chloro-2-nitro-*N*-(6-methyl-3-pyridyl)-benzoylamide; and

4-Bromomethyl-3-nitro-*N*-(6-chloro-3-pyridyl)-benzoylamide.

70. A compound selected from the group consisting of:

N-(4-Ethoxy-2-nitrophenyl)-3-pyrrolylcarboxamide;

4-Chloro-*N*-(4-ethoxy-2-nitrophenyl)-benzoylamide;

4-Chloromethyl-*N*-(4-ethoxy-2-nitrophenyl)-benzoylamide;

N-(4-Ethoxy-2-nitrophenyl)-5-pyrimidinecarboxamide;

N-(4-Ethoxy-2-nitrophenyl-2-pyridinecarboxamide; and

N-(4-Ethoxy-2-nitrophenyl)-1-*N*-oxide-2-pyridinecarboxamide.

71. A pharmaceutical composition, comprising the compound of any one of claims 58-70, and a pharmaceutically acceptable carrier.

72. The pharmaceutical composition of claim 71, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

73. The pharmaceutical composition of claim 72, wherein said known cancer chemotherapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin,

mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan® and alanosine.